Table 4. Adverse events.
| Variables | n (%) | ||||
| EP+A group (N=133) | EP group (N=92) | ||||
| Any grade | Grade 3−4 | Any grade | Grade 3−4 | ||
| EP+A, atezolizumab plus EP chemotherapy; EP, EP chemotherapy; irAE, immunotherapy-related adverse event; †, three patients had a history of thyroid dysfunction; ‡, two patients had a history of pulmonary tuberculosis; one patient had a history of emphysema; §, one patient had a history of cardiac disease. | |||||
| White blood cell decreased | 50 (37.6) | 18 (13.5) | 35 (38.0) | 8 (8.7) | |
| Neutrophil count decreased | 44 (33.1) | 30 (22.6) | 24 (26.1) | 11 (12.0) | |
| Platelet count decreased | 19 (14.3) | 7 (5.3) | 20 (21.7) | 7 (7.6) | |
| Anaemia | 14 (10.5) | 3 (2.3) | 11 (12.0) | 0 (0) | |
| Any irAE | 19 (14.3) | 1 (0.8) | − | − | |
| irAEs requiring the use of systemic corticosteroids | 8 (6.0) | 1 (0.8) | − | − | |
| irAE leading to atezolizumab discontinuation | 6 (4.5) | 1 (0.8) | − | − | |
| Rash | 5 (3.8) | 0 (0) | − | − | |
| Hypothyroidism | 5 (3.8)† | 0 (0) | − | − | |
| Pneumonitis | 6 (4.5)‡ | 0 (0) | − | − | |
| Myocarditis | 2 (1.5)§ | 0 (0) | − | − | |
| Encephalitis | 1 (0.8) | 1 (0.8) | − | − | |
| Pancreatitis | 1 (0.8) | 0 (0) | − | − | |
| Pleural effusion | 1 (0.8) | 0 (0) | − | − | |